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Platelet-leukocyte aggregation during hemodialysis. Hemodialysis is
associated with simultaneous changes in leukocytes and platelets, but it is
unclear whether these alterations affect the interactions between these cell
types. To evaluate this process, we examined the appearance of platelet
specific antigens (CD41) on leukocytes as an index of platelet-leukocyte
aggregation during hemodialysis using three different synthetic mem-
branes. Patients with end-stage renal disease (ESRD) on long-term
hemodialysis treatment were enrolled. Flow cytometric techniques and
platelet specific monoclonal antibodies (MoAb) that recognize the glyco-
protein complex on resting and activated platelets (anti-CD41), the
activated GPIIb-IIIa complex receptor (anti-LIBS1), and the p selectin
GMP14O, that is exposed on platelet plasma membrane after activation
and platelet degranulation (anti-CD62), were used. Subjects with ESRD
had a lower predialysis platelet surface expression of CD41 and LIBS1
compared to normal controls, but unchanged CD62 expression. In paral-
lel, patients with ESRD manifested a uniformly reduced platelet-leuko-
cyte microaggregates predialysis compared to normal controls. When
examined across the dialyzer, however, an increase in platelet-neutrophil
and platelet-monocyte nlicroaggregates was observed with all three syn-
thetic membranes at both 15 and 30 minutes after initiation of dialysis.
This phenomenon could be duplicated in Vitro by physiologic concentra-
tions of the platelet specific agonist ADP, but not by the complement
factors C3a or C5a. We conclude that platelet-leukocyte aggregates occur
during dialysis likely related to a primary platelet activation mechanism.
This phenomenon may serve as a new biocompatibility parameter and may
shed light on some of the biologic consequences of hemodialysis.
Abnormalities in platelet function have been among the earliest
hematological defects observed in uremia to attract intensive
study [reviewed in 1]. These early studies focused on the elucida-
tion of the mechanism of the defect in platelet function that
underlies the enhanced bleeding tendency of the untreated ure-
mic state and its correction by hemodialysis [1]. Another aspect of
platelet function, however, namely platelet activation by hemodi-
alysis, has received less attention except as an index of biocom-
patibility of dialysis membranes [2—4]. Platelet activation and
interaction with plasmatic components play a key role in hemo-
static mechanisms during hemodialysis treatment [2—4]. The role
of platelets, however, is much broader than their hemostatic
function. A dynamic interplay between platelets and circulating
cellular elements has been observed under a variety of physiologic
and pathologic states [5—10], and platelet interaction with endo-
thelium offers the theoretical possibility of wide reaching effects of
platelet activation [7, 11].
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Platelet activation occurs rapidly after onset of hemodialysis [4].
Because dialysis induced activation of blood platelets coincides
with leukocyte activation [2, 4, 7], it is possible that platelet
interaction with leukocytes occurs to a significant degree during
hemodialysis. Such a phenomenon may play an important patho-
physiological role in hemodialysis by facilitating platelet-endothe-
hal interaction by the intermediary of activated leukocytes [7, 11].
Further, study of these interactions may provide an insight into
the dynamic changes that characterize hemocompatibility aspects
of the blood dialyzer interface. To date, co-investigation of the
interplay between the different parameters of biocompatibility has
centered on plasmatic-cellular interactions (such as complement
and neutrophils). A study of platelet-leukocyte interactions would
offer the novel aspect of cellular-cellular interactions as a possible
parameter of hemocompatibility. Therefore, using flow cytometric
techniques and platelet specific monoclonal antibodies we studied
changes in platelet surface glycoproteins expression, and forma-
tion of platelet-leukocyte microaggregates during hemodialysis.
Methods
Patient population
Nine stable, end-stage renal disease (ESRD) patients, between
18 and 75 years old (mean SD, 48 18), treated with
hemodialysis for more than six months, on a stable anticoagula-
tion regimen, hematocrit above 26%, and able and willing to give
informed consent were entered in this study. The protocol of this
study was reviewed and approved by the University Ethical
Committee. Exclusion criteria included unstable clinical condi-
tions, cardiac and vascular instability, positive history for first use
syndrome, unstabilized erythropoietin dosage, or single needle
dialysis. None of the patients was known to have pre-existing
hemostatic disorders unrelated to uremia, infections, or had
received any medications known to affect platelet function for at
least two weeks prior to the study.
Study design
The study covered three weeks of treatment, with one week of
treatment on each dialyzer. The dialyzer sequence was random-
ized. Blood samples were collected for analysis during the third
treatment. The three dialyzers tested were Fresenius Hemoflow
F6OS (Polysulfone PS600, 1.3 m2, steam sterilized), Hospal Fil-
tral-lO AN69HF (PAN-methallylsulfonate, 0.85 m2, ETO-steril-
ized) and Nikkiso GLX-18GW containing a new modified PAN-
membrane with reduced negative charges (SPAN, 1.8 m2, gamma
sterilized).
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Dialysis procedure
Bicarbonate dialysate was used in all treatments. Dialyzers were
rinsed single pass with 2.0 liters of 0.9% NaCI solution containing
1000 IU heparin. Heparin was the sole anticoagulant used
throughout all treatments. A patient's individual heparin regimen
was maintained. A heparin bolus was administered systemically
before connection with the extracorporeal circuit, and five min-
utes later the extracorporeal circuit was established and a contin-
uous infusion of heparin was started. Blood flow rate, ultrafiltra-
tion volume, dialysate composition and duration of dialysis
treatment was according to the patients individual prescriptions.
Parameters were evaluated at baseline, 15, 30, and 240 minutes
and samples obtained form the inlet and outlet sides of the
dialyzer.
Monoclona! antibodies
All monoclonal antibodies (MoAb) used in this study were
conjugated with fluorescein isothiocyanate (FITC) according to
standard methods. MoAb anti-CD41 (Dianova) is a platelet-
specific anti-GPIIb-IIIa MoAb that recognizes the glycoprotein
complex on resting and activated platelets. Anti-LIBS1 (anti-
GPIIIa, generously provided by Dr. Mark Ginsberg, Research
Institute of Scripps Clinic, La Jolla, California, USA) is a confor-
mation-dependent MoAb that preferentially binds to the acti-
vated GPIIb-IIIa complex receptor [12]. Anti-CD62 (Dianova)
recognizes the p selectin GMPI4O, that is exposed on platelet
plasma membrane after platelet activation and degranulation has
occurred [13].
Flow cytometric analysis
Platelets. Flow cytometric (FACS) analysis of platelets was
performed as previously described [4, 12]. All samples were drawn
from the dialyzer inlet and outlet ports, anticoagulated with
citrate (ACD, NIH formula) at a ratio of 1 volume ACD to 7
volumes of blood, and immediately placed on crushed ice, Platelet
rich plasma (PRP) was obtained from ACD anticoagulated blood
samples after sedimenting red and white blood cells at 180 X g for
20 minutes at 4°C. Thereafter, 5 il of PRP aliquots were added to
polypropylene tubes containing a saturating concentration of
fluorescein (FITC) conjugated monoclonal antibodies in a total
volume of 50 Mj Tyrodes buffer (0.1% BSA, 0.1% glucose, 2 mM
MgCl2, 137.5 mrvi NaC1, 12 mrvi NaHCO3, 2.6 mivi KC1, pH 7.4).
After a 30-minute incubation period at room temperature in the
dark, 1 ml Tyrodes buffer was added to each vial and samples were
stored on ice. FACS analysis was performed within one hour.
Platelets were identified in the forward versus side scatter plot.
The gated platelet population was found to bind > 96% the
platelet specific monoclonal antibody anti-CD41.
Platelet-leukocyte interaction, Platelet-leukocyte interaction was
evaluated according to published methods [10, 14] with minor
modifications. In brief, MoAb anti-CD41 was used as a platelet
specific marker to evaluate platelet-leukocyte interaction. To
25 1.d of whole blood, 25 M1 Tyrodes buffer containing saturating
concentrations of MoAb anti-CD41 was added and incubated for
30 minutes at room temperature in the dark. Thereafter, red
blood cells were lysed and fixed with SIGMA lysing reagent
according to the manufacturer's protocol and kept on ice before
analysis. For flow cytometric analysis leukocytes were identified by
size and granularity in the forward versus side scatter plot.
Leukocyte subgroups, polymorphonuclear granulocytes, mono-
cytes, and lymphocytes were identified by use of subgroup specific
MoAbs. The mean intensity of fluorescence of anti-CD41 of the
leukocyte subgroups was used to characterize platelet-leukocyte
interaction. Samples were analyzed on a FACScan cytometer
(Becton Dickinson, Mountain View, California, USA) equipped
with an argon laser. The instrument was calibrated twice weekly
for fluorescence and lightscatter using 2 am calibrite beads
(Becton Dickinson). Five thousand particles were analyzed for
each sample at a constant flow rate of 50 to 150 events per second.
Logarithmic amplification was used for the fluorescence signal.
Data were collected and analyzed on a Hewlett Packard computer
equipped with FACScan software program.
In vitro studies. Platelet-leukocyte interactions were studied in
whole blood obtained from five normal volunteers and six ESRD
subjects and incubated with increasing physiologic concentrations
of ADP. To 25 iJ of whole blood, 5 d of ADP solution and 20 1,d
Tyrodes buffer containing saturating concentrations of MoAb
anti-CD41 were added and the mixture incubated for 15 minutes
at room temperature in the dark. The concentration of ADP was
calculated to achieve the final desired concentration of the
agonist. Samples were then processed as described above. For
platelet activation studies, platelet rich plasma (PRP) was ob-
tained from ACD anticoagulated blood samples as described
above. Thereafter, 5 pA of PRP aliquots were added to polypro-
pylene tubes containing 5 pA of a saturating concentration of
fluorescein (FITC) conjugated anti-LIBS1, 5 pA of ADP solution,
and 35 pA Tyrodes buffer. After a 15-minute incubation period at
room temperature in the dark, samples were processed as de-
scribed above.
Analytical methods
Blood count was done using the Coulter System T840, (Coulter,
Krefeld, Germany); C5a using Enzygnost C5a, (Behringwerke,
Marburg, Germany).
Statistics
Statistical analysis was performed using the statistical package
SPSS for Windows Vs.5.01, (SPSS Inc., Chicago, Illinois, USA).
Groups were compared by analysis of variance followed by
unpaired t-test for significant differences. Values reported are
mean standard error of the mean.
Results
Suiface expression of platelet glycoproteins
Effects of ESRD. Activation of circulating blood platelets was
assessed by surface expression of platelet glycoproteins using
MoAbs. Platelet release reaction was characterized by measuring
plasma membrane expression of granule membrane protein
GMP14O using anti-CD62. The appearance of the activated
fibrinogen receptor on GPIIb-IIIa was assayed using a conforma-
tion dependent MoAb anti LIBS1, which preferentially recognizes
a ligand induced epitope on GPIIIa [12].
Subjects with ESRD had a lower predialysis surface expression
of CD41 [ESRD 794 2 vs. normals 810 4 (mean anti-CD41
fluorescence units), P < 0.011 and LIBS1 [ESRD 287 10 vs.
normals 414 21 (mean anti-LIBS1 fluorescence units), P <0.01]
compared to normal controls, but unchanged CD62 expression
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Time mm
0 15 30 240
CD41 F6OS
PAN
SPAN
794 3
798 5
796 2
794 2
799 4
793 4
796 2
799 5
796 3
791 2
789 4
787 4
CD62 F60S
PAN
SPAN
317 12
304 7
315 15
322 15
318 11
323 14
317 13
303 20
314 10
327 16
321 7
333 15
LIBS1 F6OS
PAN
SPAN
313 26
290 15
273 10
304 12
322 16
309 16
305 9
285 13
304 18
292 19
282 10
276 13
[ESRD 329 8, normals 317 13, (mean anti-CD62 fluores-
cence units)] (Fig. 1).
Effect of hemodialysis. There was no change during dialysis in
the surface expression of any of the platelet glycoproteins studied
in the arterial blood samples suggesting no changes in the status
of platelets in the systemic circulation (Table 1).
Platelet-leukocyte aggregates
Effect of ESRD. Formation of platelet-leukocyte microaggre-
gates was studied by evaluating subpopulations of leukocytes
(neutrophils, monocytes, lymphocytes) for binding of platelet
specific anti-CD41. Patients with ESRD manifested a uniformly
reduced platelet-leukocyte microaggregates predialysis compared
to normal controls [PMN: ESRD 332 18, normal 394 18,
monocytes: ESRD 460 19, normal 541 23, lymphocytes: 65
2, normal 80 4, (mean anti-CD41 fluorescence units), P < 0.01
for all 3 cell types] (Fig. 2).
Effect of hemodia/ysis. When examined simultaneously across
the dialyzer, an increase in platelet-neutrophil microaggregates
was observed with all three synthetic membranes at both 15 and 30
minutes after initiation of dialysis (Fig. 3). The mean increase
anti-CD41 fluorescence units on neutrophils was for F6OS 48,
Fig. 2. Formation of platelet-leukocyte aggregates. Binding of platelet spe-
cific anti-CD41 MoAb was determined on leukocyte subgroups. Platelet-
leukocyte aggregates were lower in ESRD patients (La) predialysis com-
pared to normal controls (•). This was true for all 3 cell types
(neutrophils, monocytes and lymphocytes). Abbreviations are: PMN,
polymorphonuclear neutrophil; MON, monocytes; LYM, lymphocytes.
PAN 44, and SPAN 51. An identical increment was observed at 30
minutes of dialysis. A similar phenomenon was observed for
platelet-monocyte microaggregates (Fig. 4). The mean increase
anti-CD41 fluorescence units on monocytes was for F6OS 54, PAN
36, and SPAN 79. An identical increment was observed at 30
minutes of dialysis. Lymphocyte platelet interaction was minimal
and unaffected by passage across the dialyzer. When arterial
values were examined over time, there was no increase in the
systemic circulation in the prevalence of platelet-neutrophil,
-monocyte or -lymphocyte aggregates during hemodialysis (Table
2).
To determine whether cellulosic membranes show a similar
phenomenon, we evaluated seven patients being dialyzed rou-
tinely with Hemophan. When examined simultaneously across the
dialyzer, an increase in platelet-neutrophil microaggregates was
observed with Hemophan similar to the three synthetic mem-
branes. At 15 minutes after initiation of dialysis there was a step
up across the dialyzer for anti-CD41 binding to neutrophils from
410 21 to 476 24 (P < 0.05), and to monocytes from 546
27 to 633 19 (P < 0.05). The mean increase anti-CD41
fluorescence units on neutrophils and monocytes with Hemophan
was similar to that observed with the three synthetic membranes.
Effect of ADP in vitro. To have some insight into the mechanism
of the formation of platelet-leukocyte aggregates, the platelet
specific agonist ADP was added in increasing concentrations to
whole blood from five normal controls and the occurrence of
platelet-leukocyte aggregates in vitro examined. A concentration
dependent increase in platelet-neutrophil and platelet-monocyte
aggregates was observed at concentrations of ADP within the
physiologic range (Fig. 5). There was no change in platelet-
lymphocyte aggregates. The effect was saturable at ADP concen-
tration of 10 M. A similar phenomenon was observed in leuko-
cytes obtained from six subjects on hemodialysis, the peak
response, however, was lower in uremics than that observed in
normal control. At a concentration of ADP of 10 xM, the increase
in anti-CD41 binding to neutrophils in normals was 248 62,
whereas it was 142 68 in uremics (arbitrary fluorescence units,
P < 0.05). Similarly, at a concentration of ADP of 10 jx, the
increase in anti-CD41 binding to monocytes in normals was 296
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Fig. 1. Expression of antigens CD41, CD62 and LJBSI determined on
non-stimulated platelets from normal subjects (U) and patients with ESRD
(LI) prior to dialysis session. A significantly lower CD41 and LIBS1
expression were found in the uremic subjects.
Table 1. Effect of hemodialysis on platelet surface expression of CD41,
CD62 and LIBS1
PMN MON LYM
No significant change with any membrane was observed in arterial
platelet values for these parameters throughout dialysis. Values are mean
intensity of fluorescence of the respective MoAbs.
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500
400
plement system were not altered by any of the three synthetic
membranes. At every time point outlet values for C5a were higher
than inlet for both F60 and SPAN, but not for PAN. The increase
in C5a with F60 and SPAN is minimal and remains in the range
expected for highly biocompatible synthetic membranes. Further,
the high capacity of PAN to adsorb complement should be kept in
mind when this parameter is used to compare different mem-
branes.
Discussion
The results of the present study can be summarized as follows:
(1) Subjects with ESRD had a lower predialysis surface expression
of CD41 and LIBS1 compared to normal controls, but unchanged
CD62 expression; (2) with the synthetic membranes used, there
was no change during dialysis in the surface expression of any of
the platelet glycoproteins studied in the arterial blood samples,
suggesting no changes in the status of platelets in the systemic
circulation; (3) patients with ESRD manifested a reduced plate-
let-leukocyte microaggregates predialysis compared to normal
controls; (4) when examined simultaneously across the dialyzer,
an increase in platelet-neutrophil and platelet-monocyte microag-
gregates was observed with all three synthetic membranes, but not
for lymphocytes. Similar findings were obtained using a modified
cellulosic membrane. This phenomenon could be duplicated in
vitro by physiologic concentrations of the platelet specific agonist
ADP, but not by the complement factors C3a or C5a. The
occurrence of this phenomenon with membranes of differing
complement activating potential and the inability to reproduce
P<0.05 P<0.05[1 n—i
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Table 2. Effect of hemodialysis on platelet-leukocyte aggregates
Fig. 3. Effect of dialysis on platelet-neutrophil
aggregates. There was an increased formation of
platelet-neutrophil aggregates across the
dialyzer both at 15 and 30 minutes after the
start of dialysis. Symbols are: (I) dialyzer inlet;
(E) outlet. Abbreviations are. F6OS,
polysuiphone, PAN, polyacryloniti ile; SPAN,
speeiaily modified polyaciyionitrile.
F60 PAN SPAN
Fig. 4. Effect of dialysis on platelet-raonocyte
aggregates. There was an increased formation of
platelet-monocyte aggregates across the dialyzer
both at 15 and 30 minutes after the start of
dialysis. Symbols are. () dialyzer inlet; (LI)
Time, 30 minutes outlet. Abbreviations are: F6OS, polysulphone;
PAN, polyacrylonitnle; SPAN, specially
modified polyacrylonitrile.
Time mm
0 15 30 240
PMN F60
PAN
SPAN
345 36
315 22
338 38
340 37
311 27
321 37
328 36
290 26
333 39
333 29
337 27
280 25
MON F60
PAN
SPAN
486 36
437 27
455 36
462 39
440 32
445 39
462 34
421 28
451 38
474 38
451 32
422 29
No significant change with any membrane was observed in arterial
platelet-leukocyte aggregates throughout dialysis. Values are mean inten-
sity of fluorescence of anti-CD41 on the respective cells. Abbreviations
are: PMN, polymorphonuclear neutrophuls; MON, monocytes.
37, whereas it was 183 61 in uremics (arbitrary fluorescence
units, P < 0.05). The formation of platelet-leukocyte aggregates in
blood from normal controls very closely paralleled the profile of
activation by ADP of the platelet fibrinogen receptor (Fig. 5).
Addition of complement fragments (C3a, C5a) in vitro at high
physiologic concentrations had no effect on platelet-leukocyte
interactions (data not shown).
Biocompatibility parameters
A minimal non-significant decline in white cell count was
observed at 15 minutes for all three synthetic membranes, but
otherwise WBC counts were unchanged. Arterial platelet counts
were unchanged throughout treatment for the three membranes.
Dialyzer inlet C5a values, reflecting systemic status of the corn-
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the finding in vitro with complement lead us to suggest that it
appears to be complement independent.
Several defects in platelet function have been observed in
uremia, but a consistent explanatory framework for the platelet
functional impairment has yet to emerge [1]. The present study
has identified novel aspects of platelet function in patients with
ESRD independent of the effects of dialysis. Non-stimulated
uremic platelets had a reduced surface density of glycoprotein
GPIIb-IIIa (CD41) and less fibririogen receptors in an active state
(LIBSI) than non-stimulated platelets of control subjects, but the
spontaneous release reaction (as reflected in CD62) of these
circulating platelets is similar in uremics and controls. These
results suggest a defect in the expression of the fibrinogen
receptor on platelets in both its inactive and active forms (Gawaz
et a!, manuscript in preparation). The possible binding of de-
polymerized factor VIII present in uremic blood to the fibrinogen
receptor would not lead to a reduction in platelet anti-LIBS1
binding in these patients as the antibody recognizes a cryptic
epitope that is exposed by the conformational changes that follow
ligand binding be it fibrinogen, von Willebrand factor or small
peptides. The reduced binding of anti-LIBS1 in uremic platelets
therefore represents a true reduction in the active form of the
fibrinogen receptor.
During dialysis, there was no alteration in the GPIIb-IIIa
receptor density (CD41) or the functional state of the receptor
(LIBS1) in the systemic circulation, Similarly, there was no
increase in alpha granule protein expression (GMP140, CD62).
This may not be consonant with the occurrence of platelet release
reaction during dialysis, as evidenced by increased beta thrombo-
globulin in plasma [4]. This apparent discrepancy may be related
to the fact that platelets with increased GMP14O surface expres-
sion are rapidly cleared by sequestration in the microvasculature.
This may occur via adhesion molecules (selectins) either directly
with the endothelium or by mediating platelet-leukocyte micro-
aggregates [151. Alternatively, platelet consumption may be oc-
curring in the extracorporeal circuit with resultant increase in beta
thromboglobulin [4], but the fragments of these consumed plate-
lets are not detectable by FACS analysis. Quantitatively, the
magnitude of platelet clearance is not reflected in total platelet
counts in the systemic circulation which are minimally affected
during the procedure. Platelet counts are an insensitive method to
measure platelet consumption, particularly as it pertains to the
formation of platelet-leukocyte coaggregates considering the
large discrepancy in the circulating numbers of the two cell
populations.
Several investigators have reported the detection of platelet-
leukocyte co-aggregates in the circulation under normal and
pathophysiologic states [5-10]. Whether this phenomenon is a
true in vivo state or the result of in vitro alterations remains to be
determined. However, the dependence of the formation of these
co-aggregates on divalent cations and specific epitopes of the
GMP14O molecule, and the reproducible changes observed with
cardiopulmonary bypass [10] and across dialyzers in the present
study, strongly indicate that it is a real in vivo phenomenon.
Further, the induction of this phenomenon in vitro with the
platelet specific agonist ADP in physiologic concentrations favors
the consideration of this phenomenon as a true biologic event.
Taken together, these observations are consistent with a true
cell-to-cell aggregation. The theoretical possibility that part of the
signal may be due to passive adhesion of either soluble CD41 or
CD41 shed from platelets to leukocytes cannot be unequivocally
excluded based on the methods used in the present study.
The mechanisms underlying the aggregation are unclear, but
several possibilities can be advanced including roles for platelet
GMP14O, fibrinogen receptor, or other adhesion molecules.
GMP14O is an integral membrane glycoprotein constitutively
expressed in alpha granules of platelets [13]. In vitro studies have
indicated that GMP14O on activated platelets mediates the bind-
ing of platelets to neutrophils and monocytes but not to lympho-
cytes [16-48]. Platelet-leukocyte aggregation mediated by
GMP14O would be dependent on prior platelet degranulation
required to release GMPI4O which remains associated with the
plasma membrane. The counterreceptor on leukocytes would be
CD15 [19].
Others have advanced evidence supporting a role for GPIIb-
lila in mediating piatelet-leukocyte co-aggregation [20]. MACi
expression on monocytes and neutrophils is up-regulated during
hemodialysis [21, 22] and this integrin binds fibrinogen [23].
Fibrinogen ligand bridging between fibrinogen binding integrins
on platelets (GPIIb-IIIa) and granulocytes (MACi) [18] may
therefore play a role in dialysis induced platelet-leukocyte aggre-
gation. Further studies are necessary to evaluate this question. It
is clear, however, that multiple mechanisms of co-aggregation may
co-exist and the significance of each may depend on the activa-
tional state of the platelet and the leukocyte. GPIIb-IIIa is
700
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Fig. 5. iole blood from normal controls was
platelet agonist ADP and platelet-leukocyte
aggregation was determined as described in
Methods In parallel, platelet rich plasma was
stimulated with similar concentrations of ADP
and platelet activation was assessed by anti-
LIBS1 binding. ADP induced the formation of
platelet-neutrophil and platelet-monocyte
aggregates in parallel with platelet activation.
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expressed early in platelet activation and is a reversible phenom-
enon whereas GMP14O expression follows platelet degranulation.
Initial coaggregation may thus be GPIIb-IIIa dependent and as
the platelets degranulate they release GMP14O which further
contributes to coaggregation.
Whatever the underlying mechanism for this phenomenon, our
data show that uremic subjects have reduced basal platelet-
leukocyte coaggregation that may be related to a defect in platelet
adhesion molecules or the fibrinogen receptor if such interactions
are mediated by the latter. There is increasing evidence for
quantitative and qualitative defects in the fibrinogen receptor in
uremia which may explain the reduced basal co-aggregation in
ESRD subjects. In favor of such a role is the parallelism between
the known reduced platelet LIBS1 response to ADP in uremia
and the diminished anti-CD41 binding to leukocytes in response
to ADP in uremic subjects found in the present study.
We have observed an increased formation of platelet-neutro-
phil and platelet-monocyte coaggregation (as reflected in surface
expression of CD41 on these leukocytes) after passage through
the dialyzer, but no increase in platelet-leukocyte interaction. The
latter observation is not unexpected as platelet-leukocyte interac-
tion is usually very minimal [5, 10, 14]. In general, the signal for
platelet-monocyte co-aggregates has exceeded that for platelet-
neutrophil co-aggregates. This is consistent with in vitro data
showing a competitive advantage of monocytes over neutrophils
for binding to activated platelets [51.
The mechanism underlying increased platelet-neutrophil and
platelet-monocyte co-aggregates during passage through the dia-
lyzer may be due to primary activation of platelets by shear stress,
contact activation, or agonist activation. ADP-activation of plate-
let in vitro leads to a dose dependent increase in the formation of
platelet-neutrophil and platelet-monocyte co-aggregates, whereas
the addition of complement factors C3a and C5a which are
increased during dialysis has no effect on this phenomenon. The
reproduction of the phenomenon by ADP addition in vitro should
not be construed to imply that ADP per se is responsible for the
occurrence of the phenomenon of membrane receptor transfer
occurring within the dialyzer. We used ADP as a specific primary
platelet agonist to suggest that the phenomenon observed in
dialysis is related to a primary platelet activation rather than
secondary to complement activation. Whether primary leukocyte
activation may contribute to the formation of these co-aggregates
is not entirely ruled out at present.
The design of the present study was to choose synthetic
membranes associated with minimal or no leukopenia to avoid the
problem of leukocyte-subpopulation analysis. Had we chosen to
study membranes with significant leukopenia, the phenomenon
may have been obscured by the large pulmonary sequestration of
co-aggregates. We did, however, evaluate a modified cellulosic
membrane (Hemophan) with an attenuated leukopenic response
compared to unmodified cellulose, and found the induction of
platelet-leukocyte aggregates by this cellulosic membrane to be
similar to the three synthetic membranes.
While there is a step up across the dialyzer in the formation of
platelet-leukocyte co-aggregates, the level of these co-aggregates
in the systemic circulation is not altered during dialysis. Several
explanations may be advanced for this observation. The platelet-
leukocyte co-aggregates may be sequestered in the microvascula-
ture, the co-aggregation may be reversible and hence may disso-
ciate in the systemic circulation, or that the percentage of
leukocytes with platelet co-aggregates as a proportion of the
systemic leukocyte pool is small and the signal is thereby diluted
and undetected by the method employed.
The significance of co-aggregate formation resides in the mech-
anisms of cell cross-talk. Platelets, for example, supply free
cholesterol to monocytes and the latter may become involved in
foam cell generation in atherosclerotic plaques [5]. There is also
an elaborate degree of cross-talk between neutrophils and plate-
lets [6, 8]. In general, under resting conditions a reciprocal
inhibitory effect predominates. When these cells are activated,
reciprocal activation occurs thereby magnifying the response [6].
Neutrophils utilize platelet derived arachidonate to increase
leukotriene and other eicosanoid synthesis, and neutrophil de-
rived cathepsin G may induce further platelet aggregation and
secretion [8]. Further, platelets and neutrophils can cooperate to
increase the formation of platelet activating factor (PAF) which
acts on both cell types and offers the potential for amplification of
activation [8]. One serious clinical situation where platelet-neu-
trophil interactions have been implicated is in the pathophysiol-
ogy of septic shock and multiple organ system failure [7, 8, 24]. It
is intriguing to speculate, but remains to be determined, whether
the formation of platelet-leukocyte co-aggregates during dialysis
has any real pathophysiologic consequence in patients with end-
stage renal disease.
To date, co-investigation of the interplay between the different
parameters of biocompatibility has centered on plasmatic-cellular
interactions (such as complement and neutrophils) [25—271. The
evaluation of platelet-leukocyte aggregates combined with char-
acterization of surface expression of activated GPIIb-IIIa on
platelets might be a useful concept for studying biocompatibility
of dialyzer membranes. A study of platelet-leukocyte interactions
would offer the novel aspect of cellular-cellular interactions as a
possible parameter of hemocompatibility.
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